<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1377472</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Development and verification of a manganese metabolism- and immune-related genes signature for prediction of prognosis and immune landscape in gastric cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Han</surname>
<given-names>Xiaoxi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2432540"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Leng</surname>
<given-names>Chuanyu</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Shufen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shasha</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1791085"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Shuming</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Shibo</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2557180"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Mengqi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2355028"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Xiangxue</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Yangyang</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Bing</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Qi</surname>
<given-names>Weiwei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2550764"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Oncology, The Affiliated Hospital of Qingdao University</institution>, <addr-line>Qingdao</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Biomedical Centre, Qingdao University</institution>, <addr-line>Qingdao</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Fan Mo, University of British Columbia, Canada</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Qiangan Jing, Zhejiang Provincial People&#x2019;s Hospital, China</p>
<p>Daniele Vergara, University of Salento, Italy</p>
<p>Siyuan Song, Affiliated Hospital of Nanjing University of Chinese Medicine, China</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Bing Wang, <email xlink:href="mailto:wb8320091@163.com">wb8320091@163.com</email>; Weiwei Qi, <email xlink:href="mailto:qwwdz@qdu.edu.cn">qwwdz@qdu.edu.cn</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work and share first authorship</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>13</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1377472</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Han, Leng, Zhao, Wang, Chen, Wang, Zhang, Li, Lu, Wang and Qi</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Han, Leng, Zhao, Wang, Chen, Wang, Zhang, Li, Lu, Wang and Qi</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Gastric cancer (GC) poses a global health challenge due to its widespread prevalence and unfavorable prognosis. Although immunotherapy has shown promise in clinical settings, its efficacy remains limited to a minority of GC patients. Manganese, recognized for its role in the body&#x2019;s anti-tumor immune response, has the potential to enhance the effectiveness of tumor treatment when combined with immune checkpoint inhibitors.</p>
</sec>
<sec>
<title>Methods</title>
<p>Gene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases was utilized to obtain transcriptome information and clinical data for GC. Unsupervised clustering was employed to stratify samples into distinct subtypes. Manganese metabolism- and immune-related genes (MIRGs) were identified in GC by univariate Cox regression and least absolute shrinkage and selection operator (LASSO) regression analysis. We conducted gene set variation analysis, and assessed the immune landscape, drug sensitivity, immunotherapy efficacy, and somatic mutations. The underlying role of <italic>NPR3</italic> in GC was further analyzed in the single-cell RNA sequencing data and cellular experiments.</p>
</sec>
<sec>
<title>Results</title>
<p>GC patients were classified into four subtypes characterized by significantly different prognoses and tumor microenvironments. Thirteen genes were identified and established as MIRGs, demonstrating exceptional predictive effectiveness in GC patients. Distinct enrichment patterns of molecular functions and pathways were observed among various risk subgroups. Immune infiltration analysis revealed a significantly greater abundance of macrophages and monocytes in the high-risk group. Drug sensitivity analysis identified effective drugs for patients, while patients in the low-risk group could potentially benefit from immunotherapy. <italic>NPR3</italic> expression was significantly downregulated in GC tissues. Single-cell RNA sequencing analysis indicated that the expression of <italic>NPR3</italic> was distributed in endothelial cells. Cellular experiments demonstrated that <italic>NPR3</italic> facilitated the proliferation of GC cells.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>This is the first study to utilize manganese metabolism- and immune-related genes to identify the prognostic MIRGs for GC. The MIRGs not only reliably predicted the clinical outcome of GC patients but also hold the potential to guide future immunotherapy interventions for these patients.</p>
</sec>
</abstract>
<kwd-group>
<kwd>gastric cancer</kwd>
<kwd>manganese metabolism</kwd>
<kwd>immune</kwd>
<kwd>prognostic model</kwd>
<kwd>immunotherapy</kwd>
</kwd-group>
<counts>
<fig-count count="9"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="97"/>
<page-count count="19"/>
<word-count count="7578"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Cancer Immunity and Immunotherapy</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Gastric cancer (GC), arising from the stomach&#x2019;s epithelial cells, is marked by its complexity and global impact (<xref ref-type="bibr" rid="B1">1</xref>). As per Global Cancer Statistics 2020 (GLOBOCAN 2020), it ranks fifth in prevalence and fourth in lethality worldwide (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Early-stage gastric cancer can be treated with endoscopic techniques or surgery, but its stealthy early signs often lead to late-stage diagnosis (<xref ref-type="bibr" rid="B3">3</xref>). Advanced cases rely on a comprehensive approach involving systemic anti-tumor therapies, such as chemotherapy, radiation, molecular targeted therapy, and combination treatments (<xref ref-type="bibr" rid="B4">4</xref>, <xref ref-type="bibr" rid="B5">5</xref>). However, spatial and temporal heterogeneity in gastric cancer, along with challenges from the tumor microenvironment, pose obstacles like drug resistance, limited efficacy, and tumor recurrence (<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>The immunosuppressive protein programmed death receptor 1 (PD-1) (<xref ref-type="bibr" rid="B7">7</xref>), which is abundant in tumor-infiltrating lymphocytes (TILs), has been shown to prevent autoimmune diseases caused by excessive immune cell activation (<xref ref-type="bibr" rid="B7">7</xref>, <xref ref-type="bibr" rid="B8">8</xref>). The programmed death receptor-ligand 1 (PD-L1) is abundantly expressed on the cell membrane of tumor cells, and its interaction with PD-1 leads to lymphocyte death, suppression of T-cell activation, and reduction in cytokines production, ultimately enabling tumor cells to evade immune (<xref ref-type="bibr" rid="B9">9</xref>). Immunotherapy, especially through PD-1/PD-L1 inhibitors, exploits this characteristic of malignant cells to revive immune cells within the tumor microenvironment, reinstating the killing ability of T cells against cancer cells (<xref ref-type="bibr" rid="B10">10</xref>).</p>
<p>In recent years, monoclonal antibodies targeting PD-1/PD-L1 have been employed in clinical therapy, demonstrating effectiveness across various malignant tumors. These antibodies have notably exhibited anti-tumor effects and hold promise in extending overall survival (<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B13">13</xref>). Unfortunately, the effectiveness of immune checkpoint inhibitors (ICIs) is hindered by the insufficient presence of immune cells within tumor microenvironments. ICIs rely on abundant immune cells to reactivate immune responses and induce anti-tumor effects (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>). Accordingly, the efficacy of immunotherapy is restricted to few tumor subtypes (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>).</p>
<p>Numerous metals, including potassium, calcium, manganese, and others, have been identified to modulate the immune system (<xref ref-type="bibr" rid="B17">17</xref>). In organisms, manganese is abundantly distributed, usually as Mn<sup>2+</sup> (<xref ref-type="bibr" rid="B18">18</xref>). Manganese, as indispensable components in living organisms (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B20">20</xref>), have been revealed to regulate cellular biological behavior, such as gene expression (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>) and signal transduction (<xref ref-type="bibr" rid="B23">23</xref>&#x2013;<xref ref-type="bibr" rid="B25">25</xref>). During the immune surveillance process, the DNA of tumor cells activates antigen-presenting cells, particularly dendritic cells (<xref ref-type="bibr" rid="B26">26</xref>), leading to the synthesis of type I interferons (I-IFNs) and the presentation of tumor antigens to T cells (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>). This activation triggers cytotoxic T lymphocytes (CTLs) to eliminate tumor cells (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>), with the cGAS-STING pathway playing a significant role in this process (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B31">31</xref>). Manganese enhances the activity of cyclic GMP-AMP synthase (cGAS) and its downstream stimulator of interferon gene (STING), resulting in a substantial increase in type I interferon production. Manganese is a potent activator of the cGAS-STING pathway (<xref ref-type="bibr" rid="B32">32</xref>&#x2013;<xref ref-type="bibr" rid="B35">35</xref>), leading to noteworthy anticancer effects. Mice deficient in manganese exhibit a significant reduction in their anti-tumor potential. Additionally, combining manganese with immune checkpoint inhibitors or chemotherapeutic drugs has shown enhanced effectiveness across various tumor types (<xref ref-type="bibr" rid="B36">36</xref>). Consequently, the utilization of manganese in conjunction with ICIs for therapeutic interventions in malignancies holds significant promise.</p>
<p>This study sought to establish a prognostic signature for gastric cancer by combining immune-related genes (IRGs) and manganese metabolism-related genes (MRGs). We evaluated the significance of this prognostic model in relation to immunological characteristics, the efficacy of immunotherapy, somatic mutation, and drug sensitivity. In summary, our prognostic model holds the potential to identify new targets and treatments for gastric cancer, thereby contributing to more precise anti-tumor therapy.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Datasets</title>
<p>The RNA sequencing profiles and associated clinical data of GC were retrieved from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets. The TCGA-STAD dataset was utilized as a training cohort and was obtained from UCSC XENA (<ext-link ext-link-type="uri" xlink:href="https://xenabrowser.net/datapages/">https://xenabrowser.net/datapages/</ext-link>). The GSE66229 dataset was used as a validation cohort and was acquired from The Gene Expression Omnibus (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/geo/">http://www.ncbi.nlm.nih.gov/geo/</ext-link>). We employed the &#x201c;sva&#x201d; packages to eliminate batch effects in both the TCGA-STAD dataset and the GSE66229 datasets. To ensure data integrity and precision, databases employ systematic procedures to eliminate duplicate samples and samples lacking survival data. Following the exclusion of patients with incomplete clinical information, the TCGA and GEO datasets comprised 315 and 298 GC samples, respectively. The clinical features of the samples involved in our research are displayed in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>. In addition, 1399 genes associated with manganese metabolism, referred to as manganese metabolism-related genes, were retrieved from the GeneCards database (<ext-link ext-link-type="uri" xlink:href="https://www.genecards.org/">https://www.genecards.org/</ext-link>) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>). Immune-related genes, comprising 2483 genes associated with immunity, were retrieved through the ImmPort database (<ext-link ext-link-type="uri" xlink:href="https://www.immport.org/">https://www.immport.org/</ext-link>) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S2</bold>
</xref>). The flowchart depicting the procedures used in the present study is presented in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Clinical characteristics of GC patients in the TCGA and GEO dataset.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left">Characteristic</th>
<th valign="top" align="left">TCGA cohort</th>
<th valign="top" align="left">GEO cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">No. of patients</td>
<td valign="top" align="left">315</td>
<td valign="top" align="left">298</td>
</tr>
<tr>
<th valign="top" colspan="3" align="left">Status (%)</th>
</tr>
<tr>
<td valign="top" align="left">Alive</td>
<td valign="top" align="left">186 (59.0%)</td>
<td valign="top" align="left">146 (49.0%)</td>
</tr>
<tr>
<td valign="top" align="left">Dead</td>
<td valign="top" align="left">129 (41.0%)</td>
<td valign="top" align="left">152 (51.0%)</td>
</tr>
<tr>
<th valign="top" colspan="3" align="left">Age (%)</th>
</tr>
<tr>
<td valign="top" align="left">&#x2264;60</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">117 (39.3%)</td>
</tr>
<tr>
<td valign="top" align="left">&gt;60</td>
<td valign="top" align="left">&#x2013;</td>
<td valign="top" align="left">181 (60.7%)</td>
</tr>
<tr>
<th valign="top" colspan="3" align="left">Gender (%)</th>
</tr>
<tr>
<td valign="top" align="left">Male</td>
<td valign="top" align="left">199 (63.2%)</td>
<td valign="top" align="left">197 (66.1%)</td>
</tr>
<tr>
<td valign="top" align="left">Female</td>
<td valign="top" align="left">116 (36.8%)</td>
<td valign="top" align="left">101 (33.9%)</td>
</tr>
<tr>
<th valign="top" colspan="3" align="left">WHO-Stage (%)</th>
</tr>
<tr>
<td valign="top" align="left">I</td>
<td valign="middle" align="left">42 (13.3%)</td>
<td valign="middle" align="left">30 (10.1%)</td>
</tr>
<tr>
<td valign="top" align="left">II</td>
<td valign="middle" align="left">103 (32.7%)</td>
<td valign="middle" align="left">96 (32.2%)</td>
</tr>
<tr>
<td valign="top" align="left">II</td>
<td valign="middle" align="left">136 (43.2%)</td>
<td valign="middle" align="left">95 (31.9%)</td>
</tr>
<tr>
<td valign="top" align="left">IV</td>
<td valign="middle" align="left">34 (10.8%)</td>
<td valign="middle" align="left">77 (25.8%)</td>
</tr>
<tr>
<th valign="top" colspan="3" align="left">AJCC-T stage (%)</th>
</tr>
<tr>
<td valign="top" align="left">T1</td>
<td valign="middle" align="left">15 (4.8%)</td>
<td valign="middle" align="left">&#x2013;</td>
</tr>
<tr>
<td valign="top" align="left">T2</td>
<td valign="middle" align="left">65 (20.6%)</td>
<td valign="middle" align="left">186 (62.4%)</td>
</tr>
<tr>
<td valign="top" align="left">T3</td>
<td valign="middle" align="left">150 (47.6%)</td>
<td valign="middle" align="left">91 (30.5%)</td>
</tr>
<tr>
<td valign="top" align="left">T4</td>
<td valign="middle" align="left">85 (27.0%)</td>
<td valign="middle" align="left">21 (7.1%)</td>
</tr>
<tr>
<th valign="top" colspan="3" align="left">AJCC-N stage (%)</th>
</tr>
<tr>
<td valign="top" align="left">N0</td>
<td valign="middle" align="left">98 (31.1%)</td>
<td valign="middle" align="left">38 (12.8%)</td>
</tr>
<tr>
<td valign="top" align="left">N1</td>
<td valign="middle" align="left">84 (26.7%)</td>
<td valign="middle" align="left">130 (43.6%)</td>
</tr>
<tr>
<td valign="top" align="left">N2</td>
<td valign="middle" align="left">67 (21.3%)</td>
<td valign="middle" align="left">79 (26.5%)</td>
</tr>
<tr>
<td valign="top" align="left">N3</td>
<td valign="middle" align="left">66 (20.9%)</td>
<td valign="middle" align="left">51 (17.1%)</td>
</tr>
<tr>
<th valign="top" colspan="3" align="left">AJCC-M stage (%)</th>
</tr>
<tr>
<td valign="top" align="left">M0</td>
<td valign="middle" align="left">294 (93.3%)</td>
<td valign="middle" align="left">271 (90.9%)</td>
</tr>
<tr>
<td valign="top" align="left">M1</td>
<td valign="middle" align="left">21 (6.7%)</td>
<td valign="middle" align="left">27 (9.1%)</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>The flow chart displaying the entire research.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g001.tif"/>
</fig>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Screening of differentially expressed manganese metabolism- and immune-related genes</title>
<p>The raw counts of RNA-sequencing data in TCGA dataset were analyzed using the &#x201c;edgeR&#x201d; R package to identify differentially expressed genes (DEGs) in GC tumor tissues and normal tissues. DEGs were selected based on an absolute log2 fold change (|log2FC|) &gt; 1 and a significance threshold of <italic>P</italic> &lt; 0.05. We performed additional screening of immune- and manganese metabolism-related DEGs.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Functional enrichment analysis</title>
<p>Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene ontology (GO) pathway enrichment analysis were carried out on immune- and manganese metabolism-related DEGs applying the &#x201c;clusterProfiler&#x201d; package.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Unsupervised clustering based on immune- and manganese metabolism-related DEGs</title>
<p>The process of consistent clustering was carried out on immune-related and manganese metabolism-related DEGs using the &#x201c;NMF&#x201d; R package. The subtypes were then subjected to a t-distributed stochastic neighbor embedding (t-SNE) analysis. The analysis of survival differences among subtypes was conducted utilizing the &#x201c;survminer&#x201d; and &#x201c;survival&#x201d; R packages. We investigated the variations in Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) score and tumor purity among different subtypes. Additionally, the comparative analysis of immune checkpoint expression across various subgroups was assessed by Wilcoxon test. Gene Set Variation Analysis (GSVA) was applied to investigate the differences in enrichment pathways across various subtypes.</p>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>Construction and verification of MIRGs based on manganese metabolism and immune characteristics</title>
<p>Data from TCGA was analyzed using univariate Cox regression analysis to evaluate the predictive significance of DEGs associated with manganese metabolism and immune on overall survival (OS), with a threshold of <italic>P</italic> &lt; 0.01.&#xa0;A least absolute shrinkage and selection operator (LASSO) regression analysis was carried out using the R package &#x201c;glmnet&#x201d; to avoid the issue of overfitting and develop a prognostic manganese metabolism- and immune-related genes (MIRGs)-based signature. The risk scores for every sample in the training and validation set were derived via a specific formula: Risk score = &#x2211;<sup>n</sup>
<sub>i</sub> coefi * Expression (X<sub>i</sub>). The term &#x201c;Coefi&#x201d; represented the coefficient value associated with each gene, and &#x201c;Expression (Xi)&#x201d; represented each gene&#x2019;s expression value. By employing the median risk score as the criterion for division, the patients within both the training and validation datasets were categorized into high-risk and low-risk cohorts. The prognostic differences across subgroups were assessed using the log-rank test and Kaplan-Meier survival analysis, implemented in the &#x201c;survminer&#x201d; and &#x201c;survival&#x201d; R packages.</p>
<p>To evaluate the prediction accuracy and effectiveness of MIRGs, the receiver operating characteristic (ROC) curve, and time-dependent ROC (timeROC) curve were generated using the &#x201c;survivalROC&#x201d; and &#x201c;timeROC&#x201d; R packages. The predictive performance of Manganese metabolism- and immune-related genes (MIRGs) was assessed using the area under curve (AUC). To identify independent prognostic features capable of predicting survival states in gastric cancer patients, univariate and multivariate Cox regression analyses were conducted using risk scores and clinical features. Additionally, the predictive performance of MIRGs was externally validated using the GSE66229 dataset.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Establishment of a nomogram</title>
<p>&#x201c;rms&#x201d; R package to construct a nomogram that integrated clinical features and risk scores, aiming to predict overall survival at 1, 2, and 3 years. ROC curves and calibration curves were generated to evaluate the predictive effectiveness of the nomogram.</p>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>Analysis of tumor microenvironment</title>
<p>Immune cell infiltration data were derived using Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) algorithms (<xref ref-type="bibr" rid="B37">37</xref>). Enrichment scores for immunological functions were computed using the &#x201c;GSVA&#x201d; and &#x201c;GSEABase&#x201d; packages, employing single-sample gene set enrichment analysis (ssGSEA). Subsequently, Wilcoxon test was carried out to identify differences in immune functions and immune cell profiles between individuals categorized as low-risk and high-risk.</p>
</sec>
<sec id="s2_8">
<label>2.8</label>
<title>Gene set variation analysis of MIRGs</title>
<p>The &#x201c;GSVA&#x201d; package was employed to conduct GSVA analysis, aiming to investigate the molecular functions and signaling pathways associated with MIRGs.</p>
</sec>
<sec id="s2_9">
<label>2.9</label>
<title>Prediction of drug sensitivity</title>
<p>To provide management recommendations for GC, we analyzed the half-maximal inhibitory concentration (IC<sub>50</sub>) of 198 drugs sourced from the Genomics of Drug Sensitivity in Cancer (GDSC) database. The investigation utilized the &#x201c;oncoPredict&#x201d; R package. Additionally, Wilcoxon test was used to compare the sensitivity differences of commonly used medications in the clinical treatment of GC between the low-risk group and high-risk group. Moreover, Spearman correlation test was performed to examine the relationship between the IC<sub>50</sub> values of commonly used drugs and risk scores.</p>
</sec>
<sec id="s2_10">
<label>2.10</label>
<title>Responses to immunotherapy</title>
<p>Microsatellite instability (MSI) is characterized by a high mutation rate due to single nucleotide substitutions and frequent variations in short repetitive DNA sequences (<xref ref-type="bibr" rid="B38">38</xref>), resulting from a failure in DNA mismatch repair (MMR) (<xref ref-type="bibr" rid="B38">38</xref>). Subsequently, an examination was conducted to assess the mutational status of microsatellites in patients diagnosed with gastric cancer. Additionally, an investigation explored the correlation between the mutation status of microsatellites and the corresponding risk scores. The Tumor Immune Dysfunction and Exclusion (TIDE) score for each sample was obtained using the &#x201c;TIDE&#x201d; method, predicting immunotherapy efficacy, where a lower TIDE score indicates a more positive immunotherapeutic effectiveness (<xref ref-type="bibr" rid="B39">39</xref>). The immunophenoscore (IPS) of patients from TCGA-STAD was derived through The Cancer Immunome Atlas (TCIA) website (<ext-link ext-link-type="uri" xlink:href="https://tcia.at">https://tcia.at</ext-link>), enabling the prediction of the effect of immune checkpoint inhibitors such as CTLA4 and PD-1/PD-L1 antagonists (<xref ref-type="bibr" rid="B40">40</xref>). The IPS score underwent normalization, resulting in a scale ranging from 0 to 10, with a higher IPS score implying an elevated level of immunological reactivity. Furthermore, an analysis was performed on the differential expressions of immunological checkpoints among various risk groups. The Wilcoxon test was used to determine if there are statistically significant differences between two groups.</p>
</sec>
<sec id="s2_11">
<label>2.11</label>
<title>Tumor mutation burden analysis</title>
<p>Tumor mutational burden (TMB) quantifies the number of mutated bases per million bases in each tumor sample, encompassing various mutation types like missense mutations, frameshift mutations, and nonsense mutations. The TMB data for stomach adenocarcinoma were extracted from TCGA and can be accessed at <ext-link ext-link-type="uri" xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</ext-link>. The somatic point mutations in each gastric cancer sample were visualized by generating waterfall charts using the &#x201c;maftools&#x201d; R package.</p>
</sec>
<sec id="s2_12">
<label>2.12</label>
<title>Single-cell RNA-sequencing analysis</title>
<p>The single-cell RNA sequencing (scRNA-seq) dataset GSE184198 was obtained from GEO for further investigation. The &#x201c;Seurat&#x201d; R program was employed to analyze this dataset, which includes both gastric cancer and normal tissue samples. To ensure high-quality scRNA-seq data, an initial filtering process was applied to retain cells expressing a minimum of 200 genes and genes exhibiting expression in at least three cells. Additionally, cells with mitochondrial gene expression exceeding 5% were excluded. Subsequently, the scRNA-seq data were normalized, and 2000 genes with significant variability were identified. Principal component analysis (PCA) was utilized to assess the significance of principal components between tissues or cells, and the datasets were visualized using uniform manifold approximation and projection (UMAP). CellMarker 2.0 was used to annotate cells in each cluster. Differentially expressed genes for each cluster were identified using a threshold of |log2FC| &gt; 0.25. Furthermore, the distribution of the <italic>NPR3</italic> gene within the cell clusters was explored.</p>
</sec>
<sec id="s2_13">
<label>2.13</label>
<title>Single gene analysis of <italic>NPR3</italic>
</title>
<p>The <italic>NPR3</italic> gene, selected from the prognostic model, underwent additional analysis. The <italic>NPR3</italic> expression levels in normal tissues and gastric cancer were compared using the Wilcoxon test. Subsequently, ROC curve analysis and Kaplan-Meier survival analysis were performed to illustrate the prognostic significance of <italic>NPR3</italic>. Furthermore, an exploration of the correlation between different immune cells and <italic>NPR3</italic> was conducted.</p>
</sec>
<sec id="s2_14">
<label>2.14</label>
<title>Cell and reagents</title>
<p>The following cell lines, antibodies, and chemicals were employed in this research: GES-1, AGS, MKN7, SGC7901, NCI-N87 (Cell Bank of Type Culture Collection of the Chinese Academy of Sciences), anti-NPR3 (Abcam, A19038), anti-GAPDH (Proteintech, Cat No: 10494&#x2013;1-AP), anti-E-cadherin (Proteintech, Cat No: 60335&#x2013;1-Ig), anti-N-cadherin (Proteintech, Cat No: 22018&#x2013;1-AP), anti-Vimentin (Proteintech, Cat No: 10366&#x2013;1-AP), HRP Goat Anti Rabbit IgG (H+L) (Abclonal, AS014), Crystal violet (Aladdin, C110703), 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT, Aladdin: M158055) and BeyoClick &#x2122; EdU-488 Cell Proliferation Detection Kit (Beyotime, C0071S).</p>
</sec>
<sec id="s2_15">
<label>2.15</label>
<title>Establishing stably transfected cell lines</title>
<p>Jikai Gene (Shanghai, China) supplied the lentivirus (vector: GV341) used in the study. Initially, AGS and SGC7901 cells were inoculated in a 6-well plate and allowed to stabilize for 24 hours. Following this, the lentivirus was added to the culture medium, and the cells were incubated for an additional 24 hours. Subsequently, puromycin was applied to the cells for 48 hours, following the provided instructions, to identify cell lines that stably overexpress <italic>NPR3</italic> (p-NPR3).</p>
</sec>
<sec id="s2_16">
<label>2.16</label>
<title>Cell viability determination</title>
<p>AGS (1.5*10<sup>4</sup>/well) and SGC7901 (3*10<sup>4</sup>/well) cells were seeded into a 24-well plate. Cell viability was assessed on the first, third, and fifth days. At each time point, cell growth was halted, and a 0.5 mg/mL MTT solution was introduced to the 24-well plate, followed by 2&#x2013;4 hours of incubation. Subsequently, the resulting solution was dissolved in DMSO, and the absorbance was measured at 490 nm using a full-function microplate detector (BioTek, USA).</p>
</sec>
<sec id="s2_17">
<label>2.17</label>
<title>EdU assay</title>
<p>AGS and SGC7901 cells were cultured in a 24-well plate. The EdU working solution was introduced to the cell culture system when the cells were in a healthy state and they were allowed to incubate for 2 hours. Subsequently, in accordance with the provided instructions, the EDU reaction solution and DAPI were added separately. The scene was observed and photographed using an inverted fluorescence microscope (Nikon, Japan).</p>
</sec>
<sec id="s2_18">
<label>2.18</label>
<title>Migration assay</title>
<p>AGS and SGC7901 cells were inoculated for growth in a 24-well plate. Once each well was filled with cells, a wound was created on the cell surface using a tip. To assess the migratory ability of the cells, the width of the wound was measured with a microscope at 0 and 48 hours.</p>
</sec>
<sec id="s2_19">
<label>2.19</label>
<title>Colony formation assay</title>
<p>AGS (1000/well) and SGC7901 (1000/well) cells were inoculated in a 6-well plate, and the culture media were changed every three days. The cells were fixed with 4% paraformaldehyde, stained with a 0.1% crystal violet solution, and washed with tap water until the 12th day. Subsequently, the cell colonies were examined, and the count was conducted.</p>
</sec>
<sec id="s2_20">
<label>2.20</label>
<title>Western blot</title>
<p>To obtain cell proteins, cells in good growth condition were collected and lysed on ice for 1 hour in cell lysis buffer for Western and IP. Cell proteins were quantified using the BCA method, and a buffer solution was added to achieve 3000&#x3bc;g/ml. The protein was denatured by boiling in water at 100&#xb0;C for 10 minutes. Subsequently, cell proteins were subjected to electrophoresis at 80V and 120V, followed by protein transfer to polyvinylidene difluoride (PVDF) membranes at 300mA for 120 minutes.</p>
<p>The PVDF membrane was sealed at room temperature for 2 hours, then incubated overnight with anti-NPR3 and anti-GAPDH. Antibodies were diluted at a ratio of 1:1000 using 5% skim milk. Following this, HRP Goat Anti-Rabbit IgG (H+L) was left at room temperature for 2 hours before testing for protein expression.</p>
</sec>
<sec id="s2_21">
<label>2.21</label>
<title>Statistical analysis</title>
<p>The statistical analyses were conducted using R software (version 4.3.0) and GraphPad Prism Software (version 8.0.2). The independent Student&#x2019;s t-test was performed to compare normally distributed continuous data between two groups, while the Wilcoxon test was used to compare non-normally distributed continuous variables. Kruskal-Wallis test was used for comparison of continuous variables between multiple groups. The Spearman correlation test was used to measure the correlation between two variables. Experimental data were presented as means &#xb1; standard deviation (SD). <italic>P</italic> &lt; 0.05 were deemed statistically significant unless otherwise stated in the text.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title>Screening of differentially expressed manganese metabolism- and immune-related genes</title>
<p>In TCGA-STAD, a total of 4482 genes displayed differential expression between normal tissues and gastric tumor samples (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S3</bold>
</xref>). Among these genes, 2133 were upregulated, while 2349 were downregulated (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). Our analysis involved a comprehensive set of 2909 genes related to manganese metabolism and immune functions (MRGs and IRGs). From this pool, 692 genes were identified as DEGs associated with both manganese metabolism and immune functions (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>; <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S4</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Gene screening and functional enrichment analysis. <bold>(A)</bold> Volcanic plot of DEGs in TCGA-STAD. <bold>(B)</bold> Venn diagram showing 692 differentially expressed MRGs and IRGs. <bold>(C, D)</bold> Bar chart revealing the outcomes of KEGG pathways enrichment <bold>(C)</bold> and GO functional enrichment <bold>(D)</bold> of 692 differentially expressed MRGs and IRGs.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>The evaluation of functional analysis</title>
<p>The KEGG functional annotation revealed enrichment in immune activation pathways, including cytokine-cytokine receptor interaction, IL-17 signaling pathway, viral protein interaction with cytokine and cytokine receptor, Toll-like receptor signaling pathway, chemokine signaling pathway, and neuroactive ligand-receptor interaction (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>; <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S5</bold>
</xref>). The bar plot (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>) displayed the top 8 results in Biological Process (BP), Molecular Function (MF), and Cellular Component (CC) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S6</bold>
</xref>). The GO functional annotation analysis indicated that the DEGs associated with manganese metabolism and immune functions primarily play roles in cell chemotaxis, cytokine receptor binding, granulocyte chemotaxis, leukocyte migration, and cytokine-mediated signaling pathways.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Construction of the four subtypes by unsupervised clustering</title>
<p>Following cluster analysis based on manganese metabolism- and immune-associated DEGs, the entire cohort was stratified into four distinct subtypes, denoted as clusters 1, 2, 3, and 4 (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). The t-SNE analysis results are presented in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>. Furthermore, we conducted an analysis of prognostic differences among the four subtypes. As illustrated in <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3C</bold>
</xref>, there was a statistically significant difference in prognosis among the four subgroups (<italic>P</italic> &lt; 0.001). Cluster 1 exhibited longer overall survival times compared to the other clusters, predicting a more favorable prognosis for cluster 1. The variations in the tumor microenvironment among distinct subtypes were demonstrated in <xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3D&#x2013;G</bold>
</xref>. Cluster 2 showed significantly increased immunological scores and ESTIMATE scores compared to the other clusters. The tumor purity in cluster 4 was higher than in the other clusters, potentially explaining its poor prognosis. Evaluation of immunological checkpoints revealed that patients in cluster 3 had significantly elevated expression levels for most immune checkpoints compared to patients in the other subgroups (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3H</bold>
</xref>). According to the GSVA results (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3I</bold>
</xref>; <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S7</bold>
</xref>), signaling pathways linked to tumor progression, such as focal adhesion, the transforming growth factor-&#x3b2; (TGF-&#x3b2;) signaling pathway, and extracellular matrix (ECM) receptor interaction, were elevated in clusters 2 and 3. Metabolic pathways, including pyruvate metabolism, tryptophan metabolism, and fatty acid metabolism, were concentrated in Clusters 1 and 4.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Molecular subtypes based on differentially expressed MRGs and IRGs. <bold>(A)</bold> Heatmap of consensus clustering matrix (k=4) showing four clusters (C1&#xa0;=&#xa0;157; C2&#xa0;=&#xa0;66; C3&#xa0;=&#xa0;81; C4&#xa0;=&#xa0;44) for MIRGs. <bold>(B)</bold> tSNE plot depicting distribution of four clusters. <bold>(C)</bold> The Kaplan&#x2013;Meier curves displaying significant differentiation in overall survival time of patients between different phenotypes (<italic>P</italic> &lt; 0.001). <bold>(D&#x2013;G)</bold> Violin plots showing the ESTIMATE score <bold>(D)</bold>, tumor purity <bold>(E)</bold>, immune score <bold>(F)</bold> and stromal score <bold>(G)</bold> across different phenotypes. <bold>(H)</bold> The box diagrams displaying the difference of checkpoints&#x2019; expression in four clusters. <bold>(I)</bold> Heatmap of GSVA demonstrating biological functions and signaling pathways in four subgroups. (*, **, *** represent P &lt; 0.05, P &lt; 0.01, P &lt; 0.001, respectively.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g003.tif"/>
</fig>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Establishment and validation of MIRGs</title>
<p>Univariate Cox regression analysis showed a significant correlation between 22 genes and OS in GC patients within the TCGA cohorts (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>; <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S8</bold>
</xref>). Among them, LGR6 was identified as protective for GC (HR &lt; 1, <italic>P</italic> &lt; 0.01), while the remaining genes were considered risk factors (HR &gt; 1, <italic>P</italic> &lt; 0.01). LASSO regression analysis identified 13 genes as MIRGs (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4B, C</bold>
</xref>; <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S9</bold>
</xref>). Regression coefficients were computed for each of the 13 genes. Among the 13 MIRGs, 5 were classified as Manganese Metabolism-Related Genes (<italic>CD36, VCAN, SERPINE1, SLC24A2, RAG2</italic>), 3 as Immune-Related Genes (<italic>APOH, LGR6, CER1</italic>), and 5 as genes belonging to both MRGs and IRGs (<italic>VTN, NPR3, GRP, RNASE3, EGF</italic>). A patient&#x2019;s risk score was determined based on a specific formula: RiskScore = (0.086 &#xd7; CD36) + (0.024 &#xd7; <italic>VCAN</italic>) + (0.182 &#xd7; <italic>SERPINE1</italic>) + (0.065 &#xd7; <italic>VTN</italic>) + (0.011 &#xd7; <italic>NPR3</italic>) + (0.099 &#xd7; <italic>APOH</italic>) + (0.205&#xd7; <italic>GRP</italic>) + (0.027 &#xd7; <italic>SLC24A2</italic>) + (-0.108 &#xd7; <italic>LGR6</italic>) + (0.304 &#xd7; <italic>RNASE3</italic>) + (0.171 &#xd7; <italic>CER1</italic>) + (0.372 &#xd7; <italic>EGF</italic>) + (1.075 &#xd7; <italic>RAG2</italic>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Construction and verification of MIRGs. <bold>(A)</bold> Forest plot of univariate cox regression analysis screening 22 DEGs linked to survival. <bold>(B, C)</bold> LASSO regression generating 13 genes for MIRGs. <bold>(D)</bold> The Kaplan-Meier curves illustrating significant differentiation in survival of patients between risk subgroups in the TCGA cohort. <bold>(E)</bold> Distribution of survival status in the TCGA cohort. <bold>(F)</bold> Distribution of risk score in the TCGA cohort. <bold>(G)</bold> Heatmaps of 13 genes from MIRGs in the TCGA cohort. <bold>(H)</bold> ROC curves evaluating the predictive accuracy of MIRGs in the TCGA cohort. <bold>(I)</bold> The Kaplan-Meier curves illustrating significant differentiation in survival of patients between risk subgroups in the GEO cohort. <bold>(J)</bold> Distribution of survival status in the GEO cohort. <bold>(K)</bold> Distribution of risk score in the GEO cohort. <bold>(L)</bold> Heatmaps of 13 genes from MIRGs in the GEO cohort. <bold>(M)</bold> ROC curves evaluating the predictive accuracy of MIRGs in the GEO cohort.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g004.tif"/>
</fig>
<p>The median risk score of the TCGA cohort served as the threshold value to categorize GC patients in the training set into high- and low-risk groups. Kaplan-Meier survival analysis exhibited that the high-risk group of GC patients experienced an increased mortality rate and a reduced overall survival duration (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4D</bold>
</xref>). The survival outcome and risk scores of samples in the training cohort were shown in <xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4E, F</bold>
</xref>. The variances in expression of the thirteen genes among subgroups was displayed in <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4G</bold>
</xref>. The efficiency of MIRGs was evaluated using the time-dependent curve, with area under the curves (AUCs) of 0.671, 0.719, and 0.739 at 1, 2, and 3 years (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4H</bold>
</xref>). The risk score&#x2019;s AUC was 0.657, the highest among all other clinical characteristics (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1A</bold>
</xref>). The risk score for every sample in the GSE66229 dataset was determined using the same method as in TCGA. To validate MIRGs constructed from TCGA dataset, patients in the GSE66229 datasets were also separated into high- and low-risk subgroups using the same threshold. Similar outcomes were achieved in the validation cohort. Patients in high-risk groups had a significantly reduced survival duration compared to those in the low-risk group (P &lt; 0.001) (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4I</bold>
</xref>). The survival status and risk scores of samples in the validation cohort were presented in <xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4J, K</bold>
</xref>. <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4L</bold>
</xref> displayed the variances in expression of the thirteen genes between the high- and low-risk subgroups. Time-dependent ROC curve indicated favorable levels of sensitivity and specificity, with AUC values at 1, 2, and 3 years of 0.718, 0.610, and 0.610, respectively (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4M</bold>
</xref>). The risk score AUC was 0.719, reflecting that MIRGs were highly efficient in predicting the outcome of individuals with GC (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1B</bold>
</xref>). Furthermore, the univariate and multivariate Cox regression analysis illustrated that MIRGs were significant predictors for GC in both the TCGA-STAD dataset (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S1C, D</bold>
</xref>) and the GSE66229 dataset (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S1E, F</bold>
</xref>).</p>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Development of the risk score-related prognostic nomogram</title>
<p>Nomograms were developed to enhance the predictive accuracy and clinical utility for GC patients by incorporating a risk score and other prognostic indicators (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5A, D</bold>
</xref>). The overall score and the patient survival rates at one, two, and three years showed a negative connection. Calibration curves demonstrated a close correspondence between the anticipated 1-, 2-, and 3-year rates of survival and the real-world survival rates (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5B, E</bold>
</xref>). Additionally, the AUC of the nomogram ROC curve was 0.725 in the training set and 0.778 in the validation set (<xref ref-type="fig" rid="f5">
<bold>Figures&#xa0;5C, F</bold>
</xref>). These values exceeded those for gender, age, risk, and TNM stage, indicating that the nomogram exhibited significant promise in predicting survival rates for GC patients.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Development of nomograms based on clinical features and risk scores. <bold>(A, D)</bold> The nomograms predicting the 1-, 2- and 3-year survival rate of patients with GC in the TCGA cohort <bold>(A)</bold> and in the GEO cohort <bold>(D)</bold>. <bold>(B, E)</bold> Calibration curves for nomograms in the TCGA cohort <bold>(B)</bold> and in the GEO cohort <bold>(E)</bold>. <bold>(C, F)</bold> ROC curves assessing the prognostic accuracy of nomogram and other clinical features in the TCGA cohort <bold>(C)</bold> and in the GEO cohort <bold>(F)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g005.tif"/>
</fig>
</sec>
<sec id="s3_6">
<label>3.6</label>
<title>Immunological features of MIRGs</title>
<p>The immune-related scores in TCGA-STAD were computed using the CIBERSORT algorithm, allowing us to differentiate immune infiltration between risk subgroups. High-risk individuals exhibited a significant enhancement in many immunological functions, including APC co-stimulation, circulating chemokine-receptor (CCR), human leukocyte antigen (HLA), immune checkpoints, Parainflammation, type-I IFN response, type-II IFN response, and T cell co-inhibition (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6A</bold>
</xref>). The analysis of immune infiltration revealed that patients classified as high-risk exhibited a greater fraction of monocytes and M2 macrophages compared to patients classified as low-risk (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>). The immunological characteristics of distinct risk subgroups exhibited significant variation.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Immune landscape and drug sensitivity. <bold>(A, B)</bold> Evaluation of immune cell infiltration <bold>(A)</bold> and immune function <bold>(B)</bold> between risk subgroups. <bold>(C&#x2013;J)</bold> Comparison of the IC<sub>50</sub> values of 5-Fluorouracil <bold>(C)</bold>, afatinib <bold>(D)</bold>, osimertinib <bold>(E)</bold>, paclitaxel <bold>(F)</bold>, cediranib <bold>(G)</bold>, staurosporine <bold>(H)</bold>, dasatinib <bold>(I)</bold>, and dactolisib <bold>(J)</bold> between risk subgroups. <bold>(K&#x2013;R)</bold> The correlation between IC<sub>50</sub> values of 5-Fluorouracil <bold>(K)</bold>, afatinib <bold>(L)</bold>, osimertinib <bold>(M)</bold>, paclitaxel <bold>(N)</bold>, cediranib <bold>(O)</bold>, staurosporine <bold>(P)</bold>, dasatinib <bold>(Q)</bold>, dactolisib <bold>(R)</bold> and risk scores. (*, **, ***, **** represent P &lt; 0.05, P &lt; 0.01, P &lt; 0.001, P &lt; 0.0001, respectively.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g006.tif"/>
</fig>
</sec>
<sec id="s3_7">
<label>3.7</label>
<title>Pathway enrichment analysis of MIRGs</title>
<p>The purpose of conducting GSVA was to investigate the variations in the enrichment of signaling pathways or biological processes between risk subgroups (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S2A</bold>
</xref>). Patients classified as high-risk showed enrichment in various processes and pathways associated with the progress and metastasis of tumor, including focal adhesion, TGF-&#x3b2; signaling pathway, Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, and cell adhesion molecules (CAMs). Patients classified as low-risk exhibited enrichment in metabolic-related processes, specifically propanoate metabolism, butanoate metabolism, pyruvate metabolism, and pyrimidine metabolism. Additionally, gene repair-related pathways, which includes nucleotide excision repair, base excision repair, and mismatch repair, were enriched in the low-risk group.</p>
</sec>
<sec id="s3_8">
<label>3.8</label>
<title>Drug sensitivity analysis</title>
<p>We conducted a sensitivity analysis on 198 drugs sourced from&#xa0;the GDSC database (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S10</bold>
</xref>). We then examined the IC<sub>50</sub> values of clinically relevant medicines between the low-risk and high-risk groups (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6C&#x2013;J</bold>
</xref>). Furthermore, the association between IC<sub>50</sub> values of medicines and risk scores was demonstrated (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6K&#x2013;R</bold>
</xref>). The IC<sub>50</sub> values of 5-Fluorouracil, afatinib, osimertinib, and paclitaxel medicines exhibited an upward trend when the risk scores increased. Conversely, the IC<sub>50</sub> values of cediranib, dactolisib, dasatinib, and staurosporine medicines were reduced as the risk scores increased. Drug sensitivity analysis revealed that individuals classified in the high-risk groups could potentially derive therapeutic benefits from cediranib, dactolisib, dasatinib, and staurosporine. Patients categorized as low-risk demonstrated a greater propensity to benefit from 5-Fluorouracil, afatinib, osimertinib, and paclitaxel.</p>
</sec>
<sec id="s3_9">
<label>3.9</label>
<title>Evaluation of immunotherapy efficacy</title>
<p>We next performed an analysis of the distribution of microsatellite states among patients (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7A</bold>
</xref>). The percentage of individuals with microsatellite stability (MSS) was greater in both high-risk and low-risk groups. In addition, the percentage of individuals with microsatellite instability (MSI) in low-risk patients (36%) exceeded that in the high-risk patients (29%). Individuals with MSI-high (MSI-H) status had a significantly lower risk score than those with MSS and MSI-low (MSI-L) status (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7B</bold>
</xref>). This demonstrated that immunotherapy was more likely to benefit GC patients categorized as low-risk. Patients who had higher TIDE scores often experienced less sensitivity to immunotherapy. As depicted in <xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7C</bold>
</xref>, patients categorized as low-risk had significantly elevated TIDE scores, suggesting that immunotherapy might have diminished efficacy. An analysis was further conducted to assess the IPS scores of GC patients in different risk subgroups (<xref ref-type="fig" rid="f7">
<bold>Figures&#xa0;7D&#x2013;G</bold>
</xref>). We found that the IPS-CTLA4 blocker score was significantly higher in the low-risk group compared to the high-risk group. This suggested that GC patients categorized as low-risk could potentially benefit from ICIs. Moreover, the low-risk group&#x2019;s immune checkpoint expression levels were lower than those of the high-risk group (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7H</bold>
</xref>).</p>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Immunotherapy efficacy and Tumor Mutational Burden. <bold>(A)</bold> The mutation status of microsatellites. <bold>(B)</bold> The difference of the median risk scores in the three subtypes. <bold>(C)</bold> Comparison of the TIDE score between risk subgroups. <bold>(D&#x2013;G)</bold> The differences of Immunophenoscores (IPS) <bold>(D)</bold>, IPS-PD1/PD-L1/PD-L2 <bold>(E)</bold>, IPS-PD1/PD- L1/PD-L2+CTLA4 <bold>(F)</bold>, and IPS-CTLA4 <bold>(G)</bold> between risk subgroups. <bold>(H)</bold> Comparison of immune checkpoints expression between risk subgroups. <bold>(I)</bold> Correlation analysis of risk scores and TMB. <bold>(J, K)</bold> The waterfall map demonstrating mutation frequencies in high-risk group <bold>(J)</bold> and in low-risk group <bold>(K)</bold>. (*, **, *** represent P &lt; 0.05, P &lt; 0.01, P &lt; 0.001, respectively.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g007.tif"/>
</fig>
</sec>
<sec id="s3_10">
<label>3.10</label>
<title>Somatic mutation analysis</title>
<p>The TMB of each sample was computed and analyzed. The findings demonstrated that the risk score and the TMB were negatively correlated, with the high-risk group exhibiting a significantly lower TMB in contrast to the low-risk group (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7I</bold>
</xref>). Waterfall plots were generated to display the top 20 genes exhibiting the highest mutation frequencies in high-risk patients (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7J</bold>
</xref>) and low-risk patients (<xref ref-type="fig" rid="f7">
<bold>Figure&#xa0;7K</bold>
</xref>).</p>
</sec>
<sec id="s3_11">
<label>3.11</label>
<title>Single-cell RNA-sequencing data</title>
<p>The transcriptional profile of 22,240 cells were derived from the scRNA-seq data of GSE184198. Then, sixteen cell clusters were visualized by UMAP (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8A</bold>
</xref>). A heatmap was generated to display the expression of the top 5 marker genes for each cluster (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8B</bold>
</xref>). We also visualized the distribution of the marker gene for each cluster in the scatter plot (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8C</bold>
</xref>). The sixteen cell clusters could be divided into seven distinct categories of cell types: T cells, dendritic cells, B cells, epithelial cells, fibroblasts, endothelial cells, and mast cells (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8D</bold>
</xref>). Furthermore, the expression and distribution of the <italic>NPR3</italic> gene were visualized (<xref ref-type="fig" rid="f8">
<bold>Figures&#xa0;8E, F</bold>
</xref>). The data indicated that <italic>NPR3</italic> was only enriched in endothelial cells.</p>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Single-cell RNA-sequencing analysis and single gene analysis of <italic>NPR3</italic>. <bold>(A)</bold> UMAP plot of 16 cell clusters. <bold>(B)</bold> Heatmap showing the top 5 marker genes for each cluster. <bold>(C)</bold> Scatter plot depicting the distribution of the marker gene for each cluster. <bold>(D)</bold> UMAP plot of all clusters with cell-type annotations. <bold>(E, F)</bold> Scatter plot <bold>(E)</bold> and bubble plot <bold>(F)</bold> displaying the distribution of <italic>NPR3</italic> genes in clusters. <bold>(G)</bold> Differential expression of <italic>NPR3</italic> between normal tissues and gastric cancer. <bold>(H)</bold> The Kaplan-Meier survival analysis of <italic>NPR3</italic>. <bold>(I)</bold> ROC curve of <italic>NPR3</italic> in predicting survival time. <bold>(J)</bold> Correlation between various immune cells and <italic>NPR3</italic>. (*, **, ***, and ns represent p &lt; 0.05, p &lt; 0.01, p &lt; 0.001, and &#x201c;not statistically&#x201d;, respectively.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g008.tif"/>
</fig>
</sec>
<sec id="s3_12">
<label>3.12</label>
<title>Single gene analysis of <italic>NPR3</italic>
</title>
<p>The <italic>NPR3</italic> gene exhibited significantly decreased expression in GC tissues (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8G</bold>
</xref>). Individuals with high <italic>NPR3</italic> expression had a worse prognosis compared to those with low <italic>NPR3</italic> expression (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8H</bold>
</xref>). The AUC of the ROC curve was 0.636, indicating that the <italic>NPR3</italic> gene provided accurate prognostic prediction (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8I</bold>
</xref>). The <italic>NPR3</italic> gene is linked to a diverse range of immune cells, particularly mast cells, macrophages, and NK cells (<xref ref-type="fig" rid="f8">
<bold>Figure&#xa0;8J</bold>
</xref>).</p>
</sec>
<sec id="s3_13">
<label>3.13</label>
<title>Function validation of <italic>NPR3</italic> in GC</title>
<p>The <italic>NPR3</italic> gene has been implicated in the pathogenesis of clear cell renal carcinoma (<xref ref-type="bibr" rid="B41">41</xref>), osteosarcoma (<xref ref-type="bibr" rid="B42">42</xref>), colorectal cancer (<xref ref-type="bibr" rid="B43">43</xref>), and hepatocellular carcinoma (<xref ref-type="bibr" rid="B44">44</xref>). Nevertheless, the potential role of <italic>NPR3</italic> in GC remains inadequately explored. Hence, we conducted additional investigations into the effect of <italic>NPR3</italic> on GC through cellular experiments. The western blot indicated a decreased expression of <italic>NPR3</italic> in GC cell lines (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9A</bold>
</xref>). The p-NPR3 was transferred into AGS and SGC7901 cell lines, and its efficiency for transfection was verified through a western blot (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9B, C</bold>
</xref>). AGS cell viability was not affected by <italic>NPR3</italic> overexpression (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9D</bold>
</xref>), while SGC7901 cell viability was significantly increased (<xref ref-type="fig" rid="f9">
<bold>Figure&#xa0;9E</bold>
</xref>). The colony formation experiments revealed that elevated levels of <italic>NPR3</italic> expression significantly promoted the formation of colonies in the SGC7901 and AGS cell lines (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9F, G</bold>
</xref>). Furthermore, migration experiments revealed that the upregulation of <italic>NPR3</italic> expression considerably improved the migratory ability of the SGC7901 and AGS cell lines (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9H, I</bold>
</xref>). According to the results of EdU assays, the proliferation of the SGC7901 and AGS cell lines was enhanced due to <italic>NPR3</italic> upregulation (<xref ref-type="fig" rid="f9">
<bold>Figures&#xa0;9J, K</bold>
</xref>). We further explored the effect of <italic>NPR3</italic> on epithelial-mesenchymal transition (EMT) in gastric cancer cells. The protein level of mesenchymal markers, such as N-cadherin, vimentin, were considerably increased while the expression of the epithelial marker E-cadherin was notably decreased in <italic>NPR3</italic> overexpressed cells (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S3A, B</bold>
</xref>). TIMER online database was used to analyze the correlation between <italic>NPR3</italic> and EMT-related genes. The findings demonstrated that <italic>NPR3</italic> was negatively correlated with E-cadherin (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S3C</bold>
</xref>) and positively correlated with N-cadherin, vimentin (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures S3D, E</bold>
</xref>).</p>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>Function validation of <italic>NPR3</italic> in GC. <bold>(A)</bold> The expression of <italic>NPR3</italic> protein in GES-1, AGS, MKN7, SGC7901, NCI-N87 cells. <bold>(B)</bold> The expression of <italic>NPR3</italic> protein in AGS cells following transfection of p-NPR3. <bold>(C)</bold> The expression of <italic>NPR3</italic> protein in SGC7901 cells following transfection of p-NPR3. <bold>(D)</bold> Cell viability of AGS cells after transfection of p-NPR3. <bold>(E)</bold> Cell viability of SGC7901 cells after transfection of p-NPR3. <bold>(F)</bold> Clone formation of AGS cells after transfection of p-NPR3. <bold>(G)</bold> Clone formation of SGC7901 cells after transfection of p-NPR3. <bold>(H)</bold> Migration of AGS cells after transfection of p-NPR3. <bold>(I)</bold> Migration of SGC7901 cells after transfection of p-NPR3. <bold>(J)</bold> EdU assay of AGS cells after transfection of p-NPR3. <bold>(K)</bold> EdU assay of SGC7901 cells after transfection of p-NPR3. (*, ** represent P &lt; 0.05, P &lt; 0.01, respectively.).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1377472-g009.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>GC, characterized by its heterogeneity, is frequently detected at an advanced stage (<xref ref-type="bibr" rid="B1">1</xref>). Although immunotherapy has emerged as a promising treatment strategy for GC (<xref ref-type="bibr" rid="B45">45</xref>, <xref ref-type="bibr" rid="B46">46</xref>), its response rate remains suboptimal, presenting a substantial challenge in human health (<xref ref-type="bibr" rid="B1">1</xref>). Recent scientific investigations have highlighted the pivotal role of the cGAS-STING pathway in the body&#x2019;s immune response to tumors (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B29">29</xref>&#x2013;<xref ref-type="bibr" rid="B31">31</xref>). Manganese, as the activator of this pathway (<xref ref-type="bibr" rid="B32">32</xref>&#x2013;<xref ref-type="bibr" rid="B35">35</xref>), enhances the body&#x2019;s anti-tumor capacity. The combination of manganese with ICIs has demonstrated improved antitumor effectiveness (<xref ref-type="bibr" rid="B36">36</xref>). These findings indicate that exploring manganese metabolism and immunity in GC has significant clinical implications for improving patient prognosis.</p>
<p>The progress achieved in bioinformatics and sequencing technologies has led to the development of several prognostic signatures associated with immunity, particularly in assessing the prognosis of individuals with GC (<xref ref-type="bibr" rid="B47">47</xref>&#x2013;<xref ref-type="bibr" rid="B63">63</xref>). However, many prognostic models focus solely on immune-related genes, neglecting the impact of biological factors on the efficacy of immunotherapy. This study takes a novel approach by integrating research on immune and manganese metabolism, aiming to enhance the effectiveness of immunotherapy and deepen our understanding of the immunological characteristics of GC. KEGG and GO analysis revealed that DEGs associated with manganese metabolism and immune pathways were enriched in immune activation-related processes. Utilizing consensus clustering, we identified four distinct molecular subtypes, each exhibiting significant differences in survival rates. Further analysis explored the variations in tumor microenvironments, immune checkpoints, and enrichment pathways among these subtypes, confirming their impact on prognosis. Subsequently, a novel prognostic signature, termed MIRGs, was constructed, comprising 13 genes: <italic>CD36, VCAN, SERPINE1, SLC24A2, RAG2, APOH, LGR6, CER1, VTN, NPR3, GRP, RNASE3</italic>, and <italic>EGF</italic>. MIRGs effectively categorized GC patients into high-risk and low-risk groups, with the high-risk group demonstrating reduced overall survival time and poorer survival rates. Importantly, MIRGs were identified as independent predictors of the prognosis of GC patients. Nomograms were developed by combining various clinical variables with the risk score, providing a comprehensive perspective on the prognostic capabilities of MIRGs. This study, pioneering the integration of MRGs with IRGs, offers a unique and promising approach to prognostic modeling and suggests new avenues for therapeutic strategies in GC.</p>
<p>We further conducted a more in-depth investigation into the molecular mechanisms that contribute to the notable disparity in prognosis between distinct risk subgroups. The findings of immune cell infiltration analysis indicated a high proportion of monocytes and M2 macrophages in high-risk patients. Macrophages, which originate from monocytes, can be classified into two subtypes: M1 and M2 macrophages (<xref ref-type="bibr" rid="B64">64</xref>). Previous research has demonstrated that M2 macrophages are pivotal in the development and progression of GC. There is an increasing consensus (<xref ref-type="bibr" rid="B65">65</xref>, <xref ref-type="bibr" rid="B66">66</xref>) suggesting that the infiltration of M2 macrophages is strongly linked to the immune evasion environment in GC. M2 macrophages typically release pro-angiogenic molecules, such as transforming growth factor-&#x3b1; and -&#x3b2; (TGF-&#x3b1; and -&#x3b2;), vascular endothelial growth factor (VEGF), which promote angiogenesis in GC (<xref ref-type="bibr" rid="B67">67</xref>, <xref ref-type="bibr" rid="B68">68</xref>). M2 macrophages also facilitate the migration and infiltration of tumor cells by stimulating epithelial-mesenchymal transition (EMT) in GC (<xref ref-type="bibr" rid="B69">69</xref>&#x2013;<xref ref-type="bibr" rid="B71">71</xref>). In addition, M2 macrophages induce the metastasis of gastric cancer by secreting CHI3L1 (<xref ref-type="bibr" rid="B72">72</xref>). Moreover, M2 macrophages have been observed to exacerbate the advancement of GC by modifying metabolism, specifically affecting fatty acids (<xref ref-type="bibr" rid="B73">73</xref>), arginine, proline (<xref ref-type="bibr" rid="B74">74</xref>), and methionine (<xref ref-type="bibr" rid="B75">75</xref>) metabolism. A high density of M2 macrophages has been identified as a predictive indicator of unfavorable outcomes in GC (<xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). Consistently, a high abundance of M2 macrophages in patients at high risk for tumor progression and unfavorable outcomes was identified in our study. In addition to the above observation, numerous immune checkpoint expressions were substantially upregulated in individuals classified as high-risk. Immune checkpoints mediate co-inhibitory signaling pathways and induce tumor cells to evade immunosurveillance (<xref ref-type="bibr" rid="B78">78</xref>, <xref ref-type="bibr" rid="B79">79</xref>). The combination of PD-1 expressed on immune cells and PD-L1 on antigen-presenting cells and tumor cells hinders the functioning of T cells and facilitates the evasion of the immune system by tumors (<xref ref-type="bibr" rid="B80">80</xref>). Besides, it is now understood that cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibits the binding of CD28 receptors on CD4<sup>+</sup> T cells to B7 molecules on antigen-presenting cells. This activity impedes the transmission of signals from T-cell receptors, hence inhibiting their activation (<xref ref-type="bibr" rid="B81">81</xref>). T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) contributes to suppress the immune response against malignancies through multiple routes. TIGIT suppresses dendritic cell maturation (<xref ref-type="bibr" rid="B82">82</xref>), inhibits natural killer cell effector function (<xref ref-type="bibr" rid="B83">83</xref>), and promotes macrophage polarization to the M2 phenotype (<xref ref-type="bibr" rid="B84">84</xref>). A study documented that lymphocyte activation gene-3 (LAG-3) can coordinate with PD-1 to promote the immune escape of GC, indicating its potential as an indicator of poor prognosis (<xref ref-type="bibr" rid="B85">85</xref>). The elevated levels of immune checkpoints were an additional factor contributing to unfavorable prognosis of high-risk patients. The high-risk group showed enrichment in pathways linked to cancer, which involves cell adhesion molecules, the TGF-&#x3b2; signaling pathway, and the JAK-STAT signaling system, as evaluated by GSVA. Cell adhesion molecules, particularly integrins, can enhance the survival, proliferation, and infiltration of tumor cells, hence facilitating the advancement and metastasis of malignancies (<xref ref-type="bibr" rid="B86">86</xref>). The TGF-&#x3b2; signaling pathway significantly influences the development of GC (<xref ref-type="bibr" rid="B87">87</xref>). Another study revealed a significant expression of TGF-&#x3b2; protein in GC, which contributes to the malignant transformation and proliferation of tumors (<xref ref-type="bibr" rid="B88">88</xref>). Additionally, TGF-&#x3b2; is widely recognized as the main inducer for the EMT pathway in GC (<xref ref-type="bibr" rid="B89">89</xref>). The JAK-STAT signaling system plays a role in the development and progression of GC. Previous research (<xref ref-type="bibr" rid="B90">90</xref>) demonstrated that the Janus kinase (JAK) dimers facilitate the phosphorylation of tyrosine 705 of signal transducer and activator of transcription 3 (STAT3), which is excessively active in GC. STAT3 governs the transcription of genes that facilitate tumor infiltration, cancer cell proliferation, and resistance to chemotherapy (<xref ref-type="bibr" rid="B91">91</xref>, <xref ref-type="bibr" rid="B92">92</xref>). Besides, STAT3 promote mesothelial-to-mesenchymal transition and contributes to peritoneal metastasis of GC (<xref ref-type="bibr" rid="B93">93</xref>). The distinct molecular mechanisms may account for the poorer prognosis of individuals with GC who are classified as high-risk.</p>
<p>Herein, we conducted a comprehensive study on the significance of <italic>NPR3</italic> in GC. As a natriuretic peptide receptor, natriuretic peptide receptor 3 (<italic>NPR3</italic>) has been linked to the development of a variety of malignancies. Suppression of <italic>NPR3</italic> expression facilitated the spread of clear cell renal carcinoma (<xref ref-type="bibr" rid="B41">41</xref>). The induction of apoptosis in hepatocellular carcinoma cells was reported to result from the up-regulation of <italic>NPR3</italic> (<xref ref-type="bibr" rid="B44">44</xref>). The expression of <italic>NPR3</italic> inhibited the development of osteosarcoma by suppressing the PI3K-AKT pathway (<xref ref-type="bibr" rid="B42">42</xref>). In contrast, a study uncovered that <italic>NPR3</italic> overexpression promoted the proliferation of colorectal cancer cells (<xref ref-type="bibr" rid="B43">43</xref>). Moreover, <italic>NPR3</italic> was involved in constructing prognostic signatures to forecast the outcome of individuals with GC (<xref ref-type="bibr" rid="B60">60</xref>, <xref ref-type="bibr" rid="B94">94</xref>) and breast cancer (<xref ref-type="bibr" rid="B95">95</xref>&#x2013;<xref ref-type="bibr" rid="B97">97</xref>). It was found that <italic>NPR3</italic> actively stimulates the migration and proliferation of breast tumor cells (<xref ref-type="bibr" rid="B95">95</xref>). Nevertheless, the specific function of <italic>NPR3</italic> in gastric cancer has not been comprehensively examined. <italic>NPR3</italic> protein expression was demonstrated to be significantly downregulated in GC cell lines during experimental validation. The <italic>NPR3</italic> overexpression stimulated the migration and growth of GC cell lines, indicating that <italic>NPR3</italic> may function as a promoter of tumor growth in GC progression. Therefore, <italic>NPR3</italic> holds significant potential as a therapeutic and prognostic indicator for GC.</p>
<p>In summary, our research successfully developed a novel prognostic signature for gastric cancer incorporating 13 genes linked to manganese metabolism and the immune system. This prognostic signature exhibited outstanding predictive performance, providing valuable insights for clinical decision-making in GC treatment. The prospect of combining manganese with immune checkpoint inhibitors emerges as a promising avenue for future GC&#xa0;therapies. However, it is essential to acknowledge certain limitations in this research. The findings rely on publicly available&#xa0;databases and laboratory experiments conducted on isolated cells. Further investigations involving animal models and clinical trials are imperative before translating these findings into therapeutic applications.</p>
</sec>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>XH: Conceptualization, Investigation, Methodology, Writing &#x2013;&#xa0;original draft. CL: Conceptualization, Investigation, Methodology, Writing &#x2013; original draft. SZ: Data curation, Formal analysis, Writing&#xa0;&#x2013; review &amp; editing. SSW: Data curation, Formal analysis,&#xa0;Writing &#x2013; review &amp; editing. SC: Investigation, Visualization, Writing&#xa0;&#x2013; review &amp; editing. SBW: Investigation, Visualization, Writing &#x2013; review &amp; editing. MZ: Investigation, Visualization, Writing &#x2013; review &amp; editing. XL: Validation, Visualization, Writing &#x2013; review &amp; editing. YL: Validation, Visualization, Writing &#x2013; review &amp; editing. BW: Project administration, Resources, Supervision, Writing &#x2013; review &amp; editing. WQ: Funding acquisition, Project administration, Supervision, Writing&#xa0;&#x2013; review &amp; editing.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Out study was supported by the following funds: Beijing Xisike Clinical Oncology Research Foundation (Grant No. Y-BMS2019-038); Science and Technology Development Plan Project of Shandong Province (Grant No. 202003030451); The Youth Scientific Research Fund of the Affiliated Hospital of Qingdao University (Grant No. QDFYQN202101007) and Beijing Science and Technology Innovation Medical Development Foundation (Grant No. KC2021-JX-0186-145); Qingdao Key Clinical Specialty Elite Discipline.</p>
</sec>
<ack>
<title>Acknowledgments</title>
<p>We thank Home for Researchers editorial team (<ext-link ext-link-type="uri" xlink:href="http://www.home-for-researchers.com">www.home-for-researchers.com</ext-link>) for language editing service.</p>
</ack>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1377472/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1377472/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet_1.csv" id="SM1" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_2.csv" id="SM2" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_3.csv" id="SM3" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_4.csv" id="SM4" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_5.csv" id="SM5" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_6.csv" id="SM6" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_7.csv" id="SM7" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_8.csv" id="SM8" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_9.csv" id="SM9" mimetype="text/csv"/>
<supplementary-material xlink:href="DataSheet_10.csv" id="SM10" mimetype="text/csv"/>
<supplementary-material xlink:href="Image_1.tif" id="SM11" mimetype="image/tiff"/>
<supplementary-material xlink:href="Image_2.tif" id="SM12" mimetype="image/tiff"/>
<supplementary-material xlink:href="Image_3.tif" id="SM13" mimetype="image/tiff"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>HP</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>JY</given-names>
</name>
<etal/>
</person-group>. <article-title>Updates on global epidemiology, risk and prognostic factors of gastric cancer</article-title>. <source>World J Gastroenterol</source>. (<year>2023</year>) <volume>29</volume>:<page-range>2452&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3748/wjg.v29.i16.2452</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sung</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ferlay</surname> <given-names>J</given-names>
</name>
<name>
<surname>Siegel</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Laversanne</surname> <given-names>M</given-names>
</name>
<name>
<surname>Soerjomataram</surname> <given-names>I</given-names>
</name>
<name>
<surname>Jemal</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J Clin</source>. (<year>2021</year>) <volume>71</volume>:<page-range>209&#x2013;49</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rawla</surname> <given-names>P</given-names>
</name>
<name>
<surname>Barsouk</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Epidemiology of gastric cancer: global trends, risk factors and prevention</article-title>. <source>Prz Gastroenterol</source>. (<year>2019</year>) <volume>14</volume>:<fpage>26</fpage>&#x2013;<lpage>38</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.5114/pg.2018.80001</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Progress of gastric cancer surgery in the era of precision medicine</article-title>. <source>Int J Biol Sci</source>. (<year>2021</year>) <volume>17</volume>:<page-range>1041&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.7150/ijbs.56735</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joshi</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Badgwell</surname> <given-names>BD</given-names>
</name>
</person-group>. <article-title>Current treatment and recent progress in gastric cancer</article-title>. <source>CA Cancer J Clin</source>. (<year>2021</year>) <volume>71</volume>:<page-range>264&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3322/caac.21657</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>K</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Recent progress and future perspectives of immunotherapy in advanced gastric cancer</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>948647</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.948647</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pardoll</surname> <given-names>DM</given-names>
</name>
</person-group>. <article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title>. <source>Nat Rev Cancer</source>. (<year>2012</year>) <volume>12</volume>:<page-range>252&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc3239</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname> <given-names>H</given-names>
</name>
<name>
<surname>Strome</surname> <given-names>SE</given-names>
</name>
<name>
<surname>Salomao</surname> <given-names>DR</given-names>
</name>
<name>
<surname>Tamura</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hirano</surname> <given-names>F</given-names>
</name>
<name>
<surname>Flies</surname> <given-names>DB</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion</article-title>. <source>Nat Med</source>. (<year>2002</year>) <volume>8</volume>:<fpage>793</fpage>&#x2013;<lpage>800</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm730</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>X</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ge</surname> <given-names>J</given-names>
</name>
<name>
<surname>Xiang</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape</article-title>. <source>Mol Cancer</source>. (<year>2019</year>) <volume>18</volume>:<fpage>10</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12943-018-0928-4</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kono</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nakajima</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mimura</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Current status of immune checkpoint inhibitors for gastric cancer</article-title>. <source>Gastric Cancer</source>. (<year>2020</year>) <volume>23</volume>:<page-range>565&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10120-020-01090-4</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>E</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Comparative impact of PD-1 and PD-L1 inhibitors on advanced esophageal or gastric/gastroesophageal junction cancer treatment: A systematic review and meta-analysis</article-title>. <source>J Clin Med</source>. (<year>2021</year>) <volume>10</volume>:<fpage>3612</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/jcm10163612</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clarke</surname> <given-names>E</given-names>
</name>
<name>
<surname>Eriksen</surname> <given-names>JG</given-names>
</name>
<name>
<surname>Barrett</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis</article-title>. <source>Acta Oncol</source>. (<year>2021</year>) <volume>60</volume>:<page-range>1534&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/0284186X.2021.1964699</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Behrouzieh</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sheida</surname> <given-names>F</given-names>
</name>
<name>
<surname>Rezaei</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy</article-title>. <source>Expert Rev Anticancer Ther</source>. (<year>2021</year>) <volume>21</volume>:<page-range>1355&#x2013;70</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/14737140.2021.1996230</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tumeh</surname> <given-names>PC</given-names>
</name>
<name>
<surname>Harview</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Yearley</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Shintaku</surname> <given-names>IP</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>EJ</given-names>
</name>
<name>
<surname>Robert</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>PD-1 blockade induces responses by inhibiting adaptive immune resistance</article-title>. <source>Nature</source>. (<year>2014</year>) <volume>515</volume>:<page-range>568&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature13954</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagasaki</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ishino</surname> <given-names>T</given-names>
</name>
<name>
<surname>Togashi</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Mechanisms of resistance to immune checkpoint inhibitors</article-title>. <source>Cancer Sci</source>. (<year>2022</year>) <volume>113</volume>:<page-range>3303&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cas.15497</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morad</surname> <given-names>G</given-names>
</name>
<name>
<surname>Helmink</surname> <given-names>BA</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wargo</surname> <given-names>JA</given-names>
</name>
</person-group>. <article-title>Hallmarks of response, resistance, and toxicity to immune checkpoint blockade</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<page-range>5309&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2021.09.020</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>M</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Metalloimmunology: The metal ion-controlled immunity</article-title>. <source>Adv Immunol</source>. (<year>2020</year>) <volume>145</volume>:<fpage>187</fpage>&#x2013;<lpage>241</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/bs.ai.2019.11.007</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Mu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Min</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Manganese homeostasis at the host-pathogen interface and in the host immune system</article-title>. <source>Semin Cell Dev Biol</source>. (<year>2021</year>) <volume>115</volume>:<fpage>45</fpage>&#x2013;<lpage>53</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.semcdb.2020.12.006</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schroeder</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Balassa</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Tipton</surname> <given-names>IH</given-names>
</name>
</person-group>. <article-title>Essential trace metals in man: manganese. A study in homeostasis</article-title>. <source>J Chronic Dis</source>. (<year>1966</year>) <volume>19</volume>:<page-range>545&#x2013;71</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0021-9681(66)90094-4</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wedler</surname> <given-names>FC</given-names>
</name>
</person-group>. <article-title>Biological significance of manganese in mammalian systems</article-title>. <source>Prog Med Chem</source>. (<year>1993</year>) <volume>30</volume>:<fpage>89</fpage>&#x2013;<lpage>133</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0079-6468(08)70376-X</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uchida</surname> <given-names>A</given-names>
</name>
<name>
<surname>Oh-hashi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Kiuchi</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hirata</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Manganese regulates caspase-3 gene promoter activity by inducing Sp1 phosphorylation in PC12 cells</article-title>. <source>Toxicology</source>. (<year>2012</year>) <volume>302</volume>:<page-range>292&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tox.2012.08.011</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Q</given-names>
</name>
<etal/>
</person-group>. <article-title>Manganese chloride induces histone acetylation changes in neuronal cells: Its role in manganese-induced damage</article-title>. <source>Neurotoxicology</source>. (<year>2018</year>) <volume>65</volume>:<page-range>255&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.neuro.2017.11.003</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>X</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Nie</surname> <given-names>X</given-names>
</name>
<name>
<surname>Han</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Pivotal roles of p53 transcription-dependent and -independent pathways in manganese-induced mitochondrial dysfunction and neuronal apoptosis</article-title>. <source>Toxicol Appl Pharmacol</source>. (<year>2014</year>) <volume>281</volume>:<fpage>294</fpage>&#x2013;<lpage>302</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.taap.2014.10.013</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname> <given-names>DS</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>H</given-names>
</name>
<name>
<surname>Anantharam</surname> <given-names>V</given-names>
</name>
<name>
<surname>Gordon</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kanthasamy</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kanthasamy</surname> <given-names>AG</given-names>
</name>
</person-group>. <article-title>p73 gene in dopaminergic neurons is highly susceptible to manganese neurotoxicity</article-title>. <source>Neurotoxicology</source>. (<year>2017</year>) <volume>59</volume>:<page-range>231&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.neuro.2016.04.012</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>El Mchichi</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hadji</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vazquez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Leca</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>p38 MAPK and MSK1 mediate caspase-8 activation in manganese-induced mitochondria-dependent cell death</article-title>. <source>Cell Death Differ</source>. (<year>2007</year>) <volume>14</volume>:<page-range>1826&#x2013;36</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/sj.cdd.4402187</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woo</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Fuertes</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Corrales</surname> <given-names>L</given-names>
</name>
<name>
<surname>Spranger</surname> <given-names>S</given-names>
</name>
<name>
<surname>Furdyna</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Leung</surname> <given-names>MY</given-names>
</name>
<etal/>
</person-group>. <article-title>STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors</article-title>. <source>Immunity</source>. (<year>2014</year>) <volume>41</volume>:<page-range>830&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.017</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diamond</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Kinder</surname> <given-names>M</given-names>
</name>
<name>
<surname>Matsushita</surname> <given-names>H</given-names>
</name>
<name>
<surname>Mashayekhi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Dunn</surname> <given-names>GP</given-names>
</name>
<name>
<surname>Archambault</surname> <given-names>JM</given-names>
</name>
<etal/>
</person-group>. <article-title>Type I interferon is selectively required by dendritic cells for immune rejection of tumors</article-title>. <source>J Exp Med</source>. (<year>2011</year>) <volume>208</volume>:<fpage>1989</fpage>&#x2013;<lpage>2003</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20101158</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fuertes</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Kacha</surname> <given-names>AK</given-names>
</name>
<name>
<surname>Kline</surname> <given-names>J</given-names>
</name>
<name>
<surname>Woo</surname> <given-names>SR</given-names>
</name>
<name>
<surname>Kranz</surname> <given-names>DM</given-names>
</name>
<name>
<surname>Murphy</surname> <given-names>KM</given-names>
</name>
<etal/>
</person-group>. <article-title>Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells</article-title>. <source>J Exp Med</source>. (<year>2011</year>) <volume>208</volume>:<page-range>2005&#x2013;16</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20101159</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>J</given-names>
</name>
<name>
<surname>Mo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhuo</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy</article-title>. <source>Mol Cancer</source>. (<year>2020</year>) <volume>19</volume>:<fpage>133</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12943-020-01250-1</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Cui</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>cGAS-STING signaling in cancer immunity and immunotherapy</article-title>. <source>BioMed Pharmacother</source>. (<year>2021</year>) <volume>133</volume>:<fpage>110972</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biopha.2020.110972</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kwon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Bakhoum</surname> <given-names>SF</given-names>
</name>
</person-group>. <article-title>The cytosolic DNA-sensing cGAS-STING pathway in cancer</article-title>. <source>Cancer Discovery</source>. (<year>2020</year>) <volume>10</volume>:<fpage>26</fpage>&#x2013;<lpage>39</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1158/2159-8290.CD-19-0761</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Guan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Manganese Increases the Sensitivity of the cGAS-STING Pathway for Double-Stranded DNA and Is Required for the Host Defense against DNA Viruses</article-title>. <source>Immunity</source>. (<year>2018</year>) <volume>48</volume>:<fpage>675</fpage>&#x2013;<lpage>87.e7</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.017</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>H</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Manganese coordination micelles that activate stimulator of interferon genes and capture <italic>in situ</italic> tumor antigens for cancer metalloimmunotherapy</article-title>. <source>ACS Nano</source>. (<year>2022</year>) <volume>16</volume>:<page-range>16909&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acsnano.2c06926</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunogenic cell death augmented by manganese zinc sulfide nanoparticles for metastatic melanoma immunotherapy</article-title>. <source>ACS Nano</source>. (<year>2022</year>) <volume>16</volume>:<page-range>15471&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1021/acsnano.2c08013</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>R</given-names>
</name>
<name>
<surname>Du</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Luan</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation of the cGAS-STING pathway combined with CRISPR-Cas9 gene editing triggering long-term immunotherapy</article-title>. <source>Biomaterials</source>. (<year>2022</year>) <volume>291</volume>:<fpage>121871</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.biomaterials.2022.121871</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy</article-title>. <source>Cell Res</source>. (<year>2020</year>) <volume>30</volume>:<page-range>966&#x2013;79</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41422-020-00395-4</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newman</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Green</surname> <given-names>MR</given-names>
</name>
<name>
<surname>Gentles</surname> <given-names>AJ</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Robust enumeration of cell subsets from tissue expression profiles</article-title>. <source>Nat Methods</source>. (<year>2015</year>) <volume>12</volume>:<page-range>453&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nmeth.3337</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baretti</surname> <given-names>M</given-names>
</name>
<name>
<surname>Le</surname> <given-names>DT</given-names>
</name>
</person-group>. <article-title>DNA mismatch repair in cancer</article-title>. <source>Pharmacol Ther</source>. (<year>2018</year>) <volume>189</volume>:<fpage>45</fpage>&#x2013;<lpage>62</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.pharmthera.2018.04.004</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Pan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Fu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sahu</surname> <given-names>A</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</article-title>. <source>Nat Med</source>. (<year>2018</year>) <volume>24</volume>:<page-range>1550&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41591-018-0136-1</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Charoentong</surname> <given-names>P</given-names>
</name>
<name>
<surname>Finotello</surname> <given-names>F</given-names>
</name>
<name>
<surname>Angelova</surname> <given-names>M</given-names>
</name>
<name>
<surname>Mayer</surname> <given-names>C</given-names>
</name>
<name>
<surname>Efremova</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rieder</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade</article-title>. <source>Cell Rep</source>. (<year>2017</year>) <volume>18</volume>:<page-range>248&#x2013;62</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.019</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>JK</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>JZ</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Long noncoding RNA MRCCAT1 promotes metastasis of clear cell renal cell carcinoma via inhibiting NPR3 and activating p38-MAPK signaling</article-title>. <source>Mol Cancer</source>. (<year>2017</year>) <volume>16</volume>:<fpage>111</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12943-017-0681-0</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>S</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>R</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Quan</surname> <given-names>B</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>NPR3, transcriptionally regulated by POU2F1, inhibits osteosarcoma cell growth through blocking the PI3K/AKT pathway</article-title>. <source>Cell Signal</source>. (<year>2021</year>) <volume>86</volume>:<fpage>110074</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cellsig.2021.110074</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>D</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Z</given-names>
</name>
</person-group>. <article-title>Long noncoding RNA BCYRN1 promotes the proliferation of colorectal cancer cells via up-regulating NPR3 expression</article-title>. <source>Cell Physiol Biochem</source>. (<year>2018</year>) <volume>48</volume>:<page-range>2337&#x2013;49</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1159/000492649</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname> <given-names>G</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>LncRNA FENDRR Upregulation Promotes Hepatic Carcinoma Cells Apoptosis by Targeting miR-362&#x2013;5p Via NPR3 and p38-MAPK Pathway</article-title>. <source>Cancer Biother Radiopharm</source>. (<year>2020</year>) <volume>35</volume>:<page-range>629&#x2013;39</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/cbr.2019.3468</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Janjigian</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Shitara</surname> <given-names>K</given-names>
</name>
<name>
<surname>Moehler</surname> <given-names>M</given-names>
</name>
<name>
<surname>Garrido</surname> <given-names>M</given-names>
</name>
<name>
<surname>Salman</surname> <given-names>P</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial</article-title>. <source>Lancet</source>. (<year>2021</year>) <volume>398</volume>:<fpage>27</fpage>&#x2013;<lpage>40</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(21)00797-2</pub-id>
</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsueda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Graham</surname> <given-names>DY</given-names>
</name>
</person-group>. <article-title>Immunotherapy in gastric cancer</article-title>. <source>World J Gastroenterol</source>. (<year>2014</year>) <volume>20</volume>:<page-range>1657&#x2013;66</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3748/wjg.v20.i7.1657</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Weng</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>B</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Development and validation of a hypoxia-immune-based microenvironment gene signature for risk stratification in gastric cancer</article-title>. <source>J Transl Med</source>. (<year>2020</year>) <volume>18</volume>:<fpage>201</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12967-020-02366-0</pub-id>
</citation>
</ref>
<ref id="B48">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname> <given-names>B</given-names>
</name>
<name>
<surname>Meng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>BY</given-names>
</name>
<name>
<surname>Xiu</surname> <given-names>DR</given-names>
</name>
</person-group>. <article-title>Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1018413</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1018413</pub-id>
</citation>
</ref>
<ref id="B49">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zang</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Development and validation of a robust immune-related prognostic signature for gastric cancer</article-title>. <source>J Immunol Res</source>. (<year>2021</year>) <volume>2021</volume>:<fpage>5554342</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2021/5554342</pub-id>
</citation>
</ref>
<ref id="B50">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Xia</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>F</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Song</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Development and validation of an immune-related gene prognostic model for stomach adenocarcinoma</article-title>. <source>Biosci Rep</source>. (<year>2020</year>) <volume>40</volume>:<fpage>BSR20201012</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1042/BSR20201012</pub-id>
</citation>
</ref>
<ref id="B51">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>N</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical significance and prognostic role of an immune-related gene signature in gastric adenocarcinoma</article-title>. <source>Aging (Albany NY)</source>. (<year>2021</year>) <volume>13</volume>:<page-range>17734&#x2013;67</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/aging.v13i13</pub-id>
</citation>
</ref>
<ref id="B52">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>CF</given-names>
</name>
<name>
<surname>Qu</surname> <given-names>XK</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>AT</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>KP</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>JH</given-names>
</name>
</person-group>. <article-title>An immune-related prognostic signature associated with immune landscape and therapeutic responses in gastric cancer</article-title>. <source>Aging (Albany NY)</source>. (<year>2023</year>) <volume>15</volume>:<page-range>1074&#x2013;106</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/aging.204534</pub-id>
</citation>
</ref>
<ref id="B53">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>P</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Construction of an immune-related gene signature to predict survival and treatment outcome in gastric cancer</article-title>. <source>Sci Prog</source>. (<year>2021</year>) <volume>104</volume>:<fpage>36850421997286</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/0036850421997286</pub-id>
</citation>
</ref>
<ref id="B54">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ji</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Development and verification of an immune-based gene signature for risk stratification and immunotherapeutic efficacy assessment in gastric cancer</article-title>. <source>Dis Markers</source>. (<year>2021</year>) <volume>2021</volume>:<fpage>4251763</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2021/4251763</pub-id>
</citation>
</ref>
<ref id="B55">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>G</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterization of immune-related molecular subtypes and a prognostic signature correlating with the response to immunotherapy in patients with gastric cancer</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>939836</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.939836</pub-id>
</citation>
</ref>
<ref id="B56">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>B</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Comprehensive analysis of a 14 immune-related gene pair signature to predict the prognosis and immune features of gastric cancer</article-title>. <source>Int Immunopharmacol</source>. (<year>2020</year>) <volume>89</volume>:<fpage>107074</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2020.107074</pub-id>
</citation>
</ref>
<ref id="B57">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Hui</surname> <given-names>S</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>C</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Weng</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Comprehensive analysis of immune subtypes reveals the prognostic value of cytotoxicity and FAP(+) fibroblasts in stomach adenocarcinoma</article-title>. <source>Cancer Immunol Immunother</source>. (<year>2023</year>) <volume>72</volume>:<page-range>1763&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00262-023-03368-9</pub-id>
</citation>
</ref>
<ref id="B58">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Development and verification of an immune-related gene prognostic index for gastric cancer</article-title>. <source>Sci Rep</source>. (<year>2022</year>) <volume>12</volume>:<fpage>15693</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-022-20007-y</pub-id>
</citation>
</ref>
<ref id="B59">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname> <given-names>E</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>C</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>A signature of 14 immune-related gene pairs predicts overall survival in gastric cancer</article-title>. <source>Clin Transl Oncol</source>. (<year>2021</year>) <volume>23</volume>:<page-range>265&#x2013;74</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12094-020-02414-7</pub-id>
</citation>
</ref>
<ref id="B60">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tian</surname> <given-names>R</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>J</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Immune-related gene signature predicts overall survival of gastric cancer patients with varying microsatellite instability status</article-title>. <source>Aging (Albany NY)</source>. (<year>2020</year>) <volume>13</volume>:<page-range>2418&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/aging.v13i2</pub-id>
</citation>
</ref>
<ref id="B61">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>T</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Dou</surname> <given-names>R</given-names>
</name>
<name>
<surname>Xiong</surname> <given-names>B</given-names>
</name>
</person-group>. <article-title>Identification of a novel 10 immune-related genes signature as a prognostic biomarker panel for gastric cancer</article-title>. <source>Cancer Med</source>. (<year>2021</year>) <volume>10</volume>:<page-range>6546&#x2013;60</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/cam4.4180</pub-id>
</citation>
</ref>
<ref id="B62">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>L</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, Malignancy, and clinical outcomes in stomach adenocarcinoma</article-title>. <source>Aging (Albany NY)</source>. (<year>2023</year>) <volume>15</volume>:<page-range>11588&#x2013;610</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/aging.205148</pub-id>
</citation>
</ref>
<ref id="B63">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Mao</surname> <given-names>R</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Jin L. A risk model of eight immune-related genes predicting prognostic response to immune therapies for gastric cancer</article-title>. <source>Genes (Basel)</source>. (<year>2022</year>) <volume>13</volume>:<fpage>720</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/genes13050720</pub-id>
</citation>
</ref>
<ref id="B64">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mantovani</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sozzani</surname> <given-names>S</given-names>
</name>
<name>
<surname>Locati</surname> <given-names>M</given-names>
</name>
<name>
<surname>Allavena</surname> <given-names>P</given-names>
</name>
<name>
<surname>Sica</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title>. <source>Trends Immunol</source>. (<year>2002</year>) <volume>23</volume>:<page-range>549&#x2013;55</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1471-4906(02)02302-5</pub-id>
</citation>
</ref>
<ref id="B65">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Cao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical outcomes and immune metrics in intratumoral basophil-enriched gastric cancer patients</article-title>. <source>Ann Surg Oncol</source>. (<year>2021</year>) <volume>28</volume>:<page-range>6439&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1245/s10434-021-09815-0</pub-id>
</citation>
</ref>
<ref id="B66">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luo</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>N</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>P</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Lipid accumulation in macrophages confers protumorigenic polarization and immunity in gastric cancer</article-title>. <source>Cancer Sci</source>. (<year>2020</year>) <volume>111</volume>:<page-range>4000&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cas.14616</pub-id>
</citation>
</ref>
<ref id="B67">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname> <given-names>LQ</given-names>
</name>
<name>
<surname>Du</surname> <given-names>WL</given-names>
</name>
<name>
<surname>Cai</surname> <given-names>MH</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Mou</surname> <given-names>XZ</given-names>
</name>
</person-group>. <article-title>The roles of tumor-associated macrophages in tumor angiogenesis and metastasis</article-title>. <source>Cell Immunol</source>. (<year>2020</year>) <volume>353</volume>:<fpage>104119</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cellimm.2020.104119</pub-id>
</citation>
</ref>
<ref id="B68">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Riabov</surname> <given-names>V</given-names>
</name>
<name>
<surname>Gudima</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>N</given-names>
</name>
<name>
<surname>Mickley</surname> <given-names>A</given-names>
</name>
<name>
<surname>Orekhov</surname> <given-names>A</given-names>
</name>
<name>
<surname>Kzhyshkowska</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis</article-title>. <source>Front Physiol</source>. (<year>2014</year>) <volume>5</volume>:<elocation-id>75</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphys.2014.00075</pub-id>
</citation>
</ref>
<ref id="B69">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Che</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Geng</surname> <given-names>B</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Miao</surname> <given-names>X</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mu</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Helicobacter pylori-induced exosomal MET educates tumour-associated macrophages to promote gastric cancer progression</article-title>. <source>J Cell Mol Med</source>. (<year>2018</year>) <volume>22</volume>:<page-range>5708&#x2013;19</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/jcmm.13847</pub-id>
</citation>
</ref>
<ref id="B70">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guo</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Tumor-associated macrophages induce the expression of FOXQ1 to promote epithelial-mesenchymal transition and metastasis in gastric cancer cells</article-title>. <source>Oncol Rep</source>. (<year>2017</year>) <volume>38</volume>:<page-range>2003&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/or.2017.5877</pub-id>
</citation>
</ref>
<ref id="B71">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>JB</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>YX</given-names>
</name>
<name>
<surname>Ye</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>TX</given-names>
</name>
<name>
<surname>Li</surname> <given-names>P</given-names>
</name>
<name>
<surname>Lin</surname> <given-names>JX</given-names>
</name>
<etal/>
</person-group>. <article-title>CDK5RAP3 acts as a tumour suppressor in gastric cancer through the infiltration and polarization of tumour-associated macrophages</article-title>. <source>Cancer Gene Ther</source>. (<year>2023</year>) <volume>30</volume>:<fpage>22</fpage>&#x2013;<lpage>37</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41417-022-00515-9</pub-id>
</citation>
</ref>
<ref id="B72">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>X</given-names>
</name>
</person-group>. <article-title>Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein</article-title>. <source>J Hematol Oncol</source>. (<year>2017</year>) <volume>10</volume>:<fpage>36</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13045-017-0408-0</pub-id>
</citation>
</ref>
<ref id="B73">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>He</surname> <given-names>D</given-names>
</name>
<name>
<surname>He</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>USP14-mediated deubiquitination of SIRT1 in macrophage promotes fatty acid oxidation amplification and M2 phenotype polarization</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2023</year>) <volume>646</volume>:<fpage>19</fpage>&#x2013;<lpage>29</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2022.12.076</pub-id>
</citation>
</ref>
<ref id="B74">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>W</given-names>
</name>
<name>
<surname>Ni</surname> <given-names>Z</given-names>
</name>
<etal/>
</person-group>. <article-title>MSR1 characterized by chromatin accessibility mediates M2 macrophage polarization to promote gastric cancer progression</article-title>. <source>Int Immunopharmacol</source>. (<year>2022</year>) <volume>112</volume>:<fpage>109217</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.intimp.2022.109217</pub-id>
</citation>
</ref>
<ref id="B75">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>P</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer</article-title>. <source>J Immunother Cancer</source>. (<year>2021</year>) <volume>9</volume>:<fpage>e001364</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jitc-2020-001364</pub-id>
</citation>
</ref>
<ref id="B76">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>QW</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Gong</surname> <given-names>CY</given-names>
</name>
<name>
<surname>Shi</surname> <given-names>HS</given-names>
</name>
<name>
<surname>Zeng</surname> <given-names>YH</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>XZ</given-names>
</name>
<etal/>
</person-group>. <article-title>Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature</article-title>. <source>PloS One</source>. (<year>2012</year>) <volume>7</volume>:<elocation-id>e50946</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0050946</pub-id>
</citation>
</ref>
<ref id="B77">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>CW</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>GF</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>WQ</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>XJ</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>CQ</given-names>
</name>
<etal/>
</person-group>. <article-title>Distribution pattern of tumor associated macrophages predicts the prognosis of gastric cancer</article-title>. <source>Oncotarget</source>. (<year>2017</year>) <volume>8</volume>:<page-range>92757&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.18632/oncotarget.v8i54</pub-id>
</citation>
</ref>
<ref id="B78">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Finn</surname> <given-names>OJ</given-names>
</name>
</person-group>. <article-title>Cancer immunology</article-title>. <source>N Engl J Med</source>. (<year>2008</year>) <volume>358</volume>:<page-range>2704&#x2013;15</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMra072739</pub-id>
</citation>
</ref>
<ref id="B79">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brahmer</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Tykodi</surname> <given-names>SS</given-names>
</name>
<name>
<surname>Chow</surname> <given-names>LQ</given-names>
</name>
<name>
<surname>Hwu</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Topalian</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Hwu</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Safety and activity of anti-PD-L1 antibody in patients with advanced cancer</article-title>. <source>N Engl J Med</source>. (<year>2012</year>) <volume>366</volume>:<page-range>2455&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMoa1200694</pub-id>
</citation>
</ref>
<ref id="B80">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goel</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>Cancer immunotherapy in clinical practice &#x2013; the past, present, and future</article-title>. <source>Chin J Cancer</source>. (<year>2014</year>) <volume>33</volume>:<page-range>445&#x2013;57</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5732/cjc.014.10123</pub-id>
</citation>
</ref>
<ref id="B81">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sznol</surname> <given-names>M</given-names>
</name>
<name>
<surname>Melero</surname> <given-names>I</given-names>
</name>
</person-group>. <article-title>Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy</article-title>. <source>Ann Oncol</source>. (<year>2021</year>) <volume>32</volume>:<page-range>295&#x2013;7</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.annonc.2020.11.018</pub-id>
</citation>
</ref>
<ref id="B82">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Harden</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gonzalez</surname> <given-names>LC</given-names>
</name>
<name>
<surname>Francesco</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chiang</surname> <given-names>E</given-names>
</name>
<name>
<surname>Irving</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells</article-title>. <source>Nat Immunol</source>. (<year>2009</year>) <volume>10</volume>:<fpage>48</fpage>&#x2013;<lpage>57</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.1674</pub-id>
</citation>
</ref>
<ref id="B83">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Johnston</surname> <given-names>RJ</given-names>
</name>
<name>
<surname>Comps-Agrar</surname> <given-names>L</given-names>
</name>
<name>
<surname>Hackney</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Huseni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function</article-title>. <source>Cancer Cell</source>. (<year>2014</year>) <volume>26</volume>:<page-range>923&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.ccell.2014.10.018</pub-id>
</citation>
</ref>
<ref id="B84">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brauneck</surname> <given-names>F</given-names>
</name>
<name>
<surname>Fischer</surname> <given-names>B</given-names>
</name>
<name>
<surname>Witt</surname> <given-names>M</given-names>
</name>
<name>
<surname>Muschhammer</surname> <given-names>J</given-names>
</name>
<name>
<surname>Oelrich</surname> <given-names>J</given-names>
</name>
<name>
<surname>da Costa Avelar</surname> <given-names>PH</given-names>
</name>
<etal/>
</person-group>. <article-title>TIGIT blockade repolarizes AML-associated TIGIT(+) M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis</article-title>. <source>J Immunother Cancer</source>. (<year>2022</year>) <volume>10</volume>:<fpage>e004794</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1136/jitc-2022-004794</pub-id>
</citation>
</ref>
<ref id="B85">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takaya</surname> <given-names>S</given-names>
</name>
<name>
<surname>Saito</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ikeguchi</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Upregulation of immune checkpoint molecules, PD-1 and LAG-3, on CD4+ and CD8+ T cells after gastric cancer surgery</article-title>. <source>Yonago Acta Med</source>. (<year>2015</year>) <volume>58</volume>:<fpage>39</fpage>&#x2013;<lpage>44</lpage>.</citation>
</ref>
<ref id="B86">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Desgrosellier</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Cheresh</surname> <given-names>DA</given-names>
</name>
</person-group>. <article-title>Integrins in cancer: biological implications and therapeutic opportunities</article-title>. <source>Nat Rev Cancer</source>. (<year>2010</year>) <volume>10</volume>:<fpage>9</fpage>&#x2013;<lpage>22</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nrc2748</pub-id>
</citation>
</ref>
<ref id="B87">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hata</surname> <given-names>A</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>YG</given-names>
</name>
</person-group>. <article-title>TGF-&#x3b2; Signaling from receptors to smads</article-title>. <source>Cold Spring Harb Perspect Biol</source>. (<year>2016</year>) <volume>8</volume>:<fpage>a022061</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1101/cshperspect.a022061</pub-id>
</citation>
</ref>
<ref id="B88">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname> <given-names>H</given-names>
</name>
<name>
<surname>Li</surname> <given-names>XU</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects and mechanisms of blocking the hedgehog signaling pathway in human gastric cancer cells</article-title>. <source>Oncol Lett</source>. (<year>2015</year>) <volume>9</volume>:<fpage>1997</fpage>&#x2013;<lpage>2002</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/ol.2015.3032</pub-id>
</citation>
</ref>
<ref id="B89">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lei</surname> <given-names>ZN</given-names>
</name>
<name>
<surname>Teng</surname> <given-names>QX</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>W</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Signaling pathways and therapeutic interventions in gastric cancer</article-title>. <source>Signal Transduct Target Ther</source>. (<year>2022</year>) <volume>7</volume>:<fpage>358</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41392-022-01190-w</pub-id>
</citation>
</ref>
<ref id="B90">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siveen</surname> <given-names>KS</given-names>
</name>
<name>
<surname>Sikka</surname> <given-names>S</given-names>
</name>
<name>
<surname>Surana</surname> <given-names>R</given-names>
</name>
<name>
<surname>Dai</surname> <given-names>X</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Kumar</surname> <given-names>AP</given-names>
</name>
<etal/>
</person-group>. <article-title>Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors</article-title>. <source>Biochim Biophys Acta</source>. (<year>2014</year>) <volume>1845</volume>:<page-range>136&#x2013;54</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbcan.2013.12.005</pub-id>
</citation>
</ref>
<ref id="B91">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ashrafizadeh</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zarrabi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Orouei</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zarrin</surname> <given-names>V</given-names>
</name>
<name>
<surname>Rahmani Moghadam</surname> <given-names>E</given-names>
</name>
<name>
<surname>Zabolian</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>STAT3 pathway in gastric cancer: signaling, therapeutic targeting and future prospects</article-title>. <source>Biol (Basel)</source>. (<year>2020</year>) <volume>9</volume>:<fpage>126</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/biology9060126</pub-id>
</citation>
</ref>
<ref id="B92">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lv</surname> <given-names>X</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>X</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Peng</surname> <given-names>P</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells</article-title>. <source>Oncogenesis</source>. (<year>2021</year>) <volume>10</volume>:<fpage>8</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41389-020-00292-w</pub-id>
</citation>
</ref>
<ref id="B93">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>W</given-names>
</name>
</person-group>. <article-title>STAT3 promotes peritoneal metastasis of gastric cancer by enhancing mesothelial-mesenchymal transition</article-title>. <source>Biol Chem</source>. (<year>2021</year>) <volume>402</volume>:<page-range>739&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1515/hsz-2021-0120</pub-id>
</citation>
</ref>
<ref id="B94">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Lu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>A signature of seven immune-related genes predicts overall survival in male gastric cancer patients</article-title>. <source>Cancer Cell Int</source>. (<year>2021</year>) <volume>21</volume>:<fpage>117</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12935-021-01823-0</pub-id>
</citation>
</ref>
<ref id="B95">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname> <given-names>W</given-names>
</name>
<name>
<surname>He</surname> <given-names>X</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>C</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>M</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>A novel immune score model predicting the prognosis and immunotherapy response of breast cancer</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>6403</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-023-31153-2</pub-id>
</citation>
</ref>
<ref id="B96">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>WJ</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>YQ</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>YY</given-names>
</name>
<name>
<surname>Qi</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Assessing the prognostic value of stemness-related genes in breast cancer patients</article-title>. <source>Sci Rep</source>. (<year>2020</year>) <volume>10</volume>:<fpage>18325</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-020-73164-3</pub-id>
</citation>
</ref>
<ref id="B97">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yao</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>R</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Development of a novel immune-related gene prognostic index for breast cancer</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>845093</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.845093</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>